

31 March 2026

Oncology Treatments

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

All stage NSCLC figures

- **Atezolizumab (Tecentriq)**
0

- **Durvalumab (Imfinzi)**
<5

- **Nivolumab (Opdivo)**
0

- **Pembrolizumab (Keytruda)**
monotherapy - 18

- **Chemotherapy**
32

- **Radiotherapy**
Dec '25 – 33
Jan '26 – 25
Feb '26 – 19
Total - 77

- **Chemotherapy AND Radiotherapy**
11

- **Osimertinib**
monotherapy - 6

Q2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?

All stages melanoma - 34 (*RISOH does not record stage*)